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Metabolic syndromeAbnormally elevated lipid and glucose levels due to the disruption of metabolic homeostasis play causative roles
in the development of metabolic diseases. A cluster of metabolic conditions, including dyslipidemia, abdominal
obesity, and insulin resistance, is referred to as metabolic syndrome, which has been increasing globally at an
alarming rate. The primary nuclear bile acid receptor, Farnesoid X Receptor (FXR, NR1H4), plays important roles
in controlling lipid and glucose levels by regulating expression of target genes in response to bile acid signaling in
enterohepatic tissues. In this review, I discuss how signal-dependent FXR transcriptional activity is dynamically
regulated under normal physiological conditions and how it is dysregulated inmetabolic disease states. I focus on
the emerging roles of post-translational modiﬁcations (PTMs) and transcriptional cofactors in modulating FXR
transcriptional activity and pathways. Dysregulation of nuclear receptor transcriptional signaling due to aberrant
PTMs and cofactor interactions are key determinants in the development of metabolic diseases. Therefore,
targeting such abnormal PTMsand transcriptional cofactors of FXR indisease statesmayprovide a newmolecular
strategy for development of pharmacological agents to treat metabolic syndrome. This article is part of a Special
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Metabolic syndrome affects almost one-third of adults in the
United States and is increasing globally at an alarming rate [1]. It is,
therefore, important to understand the molecular mechanisms that
control metabolic pathways in normal and disease states, so that new
strategies for therapeutic interventions can be developed. The
primary nuclear bile acid receptor, Farnesoid X Receptor (FXR,
NR1H4), plays an important role in controlling metabolite levels by
activating or repressing groups of its target genes that regulate lipid
and glucose metabolism [2–6]. Despite recent advances in under-
standing the biology of FXR, how FXR regulates its target genes and
how FXR activity is modulated are poorly understood. Nuclear
receptors (NRs), including FXR, act as biosensors for extracellular
signals and transmit those signals to transcriptional machinery toalter expression of target genes [7–9]. In response to various cellular
signals, including endocrine steroid/thyroid hormones, vitamins, and
dietary lipids, NRs recruit distinct combinations of numerous
transcriptional cofactors to effectively modulate transcription of
their target genes [8,9]. Some of these cofactors can profoundly
modulate NR-mediated transcriptional responses by catalyzing post-
translational modiﬁcations (PTMs) of histones at the NR target genes
and also by catalyzing PTMs of non-histone proteins involved in
transcriptional regulation, including the NRs and their cofactors [8,9].
A number of excellent reviews highlighting the biological functions of
FXR in health and disease have been recently published [2–6,10–12].
Therefore, in this article, I focus on how FXR transcriptional signaling
is regulated under normal conditions by transcriptional cofactors and
PTMs and how FXR signaling is dysregulated in metabolic disease.
2. FXR as the primary nuclear bile acid receptor
2.1. FXR as a member of the NR superfamily
Nuclear receptors (NRs) are ligand-regulated transcription factors
that function as transcriptional switches in response to lipophilic
signaling molecules, including endocrine hormones, vitamins, xeno-
biotics, and dietary lipids [7]. They bind to speciﬁc DNA sequences
and, thereby, regulate expression of target genes that are involved in
every aspect of mammalian physiology. FXR is a member of the NR
family [7]. FXR was originally cloned in 1995 as a novel Retinoid X
Receptor (RXR, NR2B1) interacting protein (RIP14) and characterized
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FXR is expressed mainly in liver, intestine, and kidney but is also
expressed in the adrenal gland, pancreas, and reproductive tissues [2–
5,10,12]. Human and mouse genes encode four isoforms, FXR 1, α2,
α3, α4, as a result of alternative use of two different promoters and
alternative splicing between exons 5 and 6 [2–5,10,12]. Whether
these isoforms have distinct cellular and physiological functions in the
regulation of FXR target genes is unclear.
2.2. FXR ligands
FXR is a biosensor for endogenous bile acids [2–5,10,12]. A primary
bile acid, chenodeoxy cholic acid (CDCA), is the most potent natural
FXR agonist with a half maximal effective concentration (EC50) value
of about 10 μM. Secondary bile acids, lithocholic acid (LCA) and
deoxycholic acid (DCA), also activate FXR, but to a lesser extent
[2,5,10,11]. Gugglesterone, a gugglipid from the mukul tree, has been
reported to be a FXR antagonist [15]. Bile acids were shown to activate
nuclear receptors, PXR, CAR, and vitamin D receptor in addition to FXR
and also to activate cell signaling kinase pathways [2–5,10,12].
Recently, a G protein-coupled receptor (GPCR), TGR5, was identiﬁed
as a membrane bile acid receptor [6,12,16,17]. Because bile acids can
activate multiple signaling pathways, speciﬁc synthetic agonists,
including GW4064 and fexaramine, and a semi-synthetic agonist,
6E-CDCA, have provided powerful tools to dissect FXR-speciﬁc
transcriptional signaling [3,4,6,12,18,19]. Structural analysis of the
rat and human FXR LBD bound to synthetic or natural ligands and
coactivator peptides has revealed signiﬁcant insights in the mecha-
nisms of FXR activation by its ligands [19,20]. Amino acids involved in
receptor-ligand interaction are conserved between species. Although
FXR LBD contains a general organization of 12 α-helix bundles like
other NRs, unexpected ﬁndings associated with bile acid binding and
activation of FXR by coactivators were observed. Bile acids occupy the
FXR LBD binding pocket in the reverse orientation compared to
ligands for other NRs [20]. Furthermore, when bound to a ligand, FXR
has two docking sites for interaction with LXXLL motifs, which results
in a cooperative increase in binding afﬁnity for coactivators, which
contain more than one LXXLL NR interaction domain [20].
2.3. FXR DNA binding motifs
FXR, upon heterodimerization with RXRα, binds to DNA
sequences, called FXR response elements (FXREs), and activates
transcription of target genes [2–5,10,11]. The FXRE contains two
copies of a six nucleotide sequence (AGGTCA or closely related
sequences) arranged as inverted repeats separated by one nucleotide,
called IR1. The FXR/RXRα heterodimer also binds to and activates a
variety of other FXREs, such as IR0, IR8, ER8, or DR1, but binds to the
consensus IR-1 sequence with the highest afﬁnity [2–5,10]. In rare
cases, negative FXREs have been found in FXR target genes, such as
ApoA1, ApoCIII, and UGT2B4 [2–5,10,21]. FXR was shown to bind to
the ApoA1 gene as a monomer, which is associated with repression of
the gene [22]. However, whether these unusual FXREs, including the
negative FXREs, play signiﬁcant roles in mediating regulation of
transcription by FXR and the precise molecular mechanisms by which
FXR binds to its target genes as a monomer and represses their
transcription are not clearly understood.
Chromatin immunoprecipitation followed by deep sequencing
(ChIP–seq) is a powerful technique for the identiﬁcation of direct
binding sites for transcription factors in the entire genome. Guo and
colleagues recently identiﬁed tissue-speciﬁc FXR-binding sites in liver
and intestine by ChIP–seq analysis of mice treated with GW4064 [23].
Only 11% of total sites were shared between liver and intestine,
demonstrating tissue-speciﬁc FXR/gene interactions. Analysis of the
binding motifs revealed that a half nuclear receptor binding site was
often located adjacent to the FXREs, indicating possible involvement ofother nuclear receptors in modulating FXR function. Consistent with
these ﬁndings, Osborne and colleagues reported that LRH-1, as a
monomeric nuclear receptor partner for FXR, binds to a nuclear receptor
half site near the FXRE to co-activate gene expression [24]. Consistent
with previous in vitro studies [2–5,10], themost common FXRE in these
studies was the IR1 motif [23,24]. Gene ontology analyses revealed
broader biological functions of FXR than previously appreciated. FXR-
binding sites were detected close to many genes involved in lipid, fatty
acid, and steroid metabolism but also to other broad gene clusters
related to metabolism, transport, kinase signaling, and glycolysis.
3. Functions of FXR
FXR-null mice, synthetic FXR ligands, and gene proﬁling analyses
have been extensively used to analyze the biological functions of FXR
[2–6,10,25]. A number of excellent articles reviewing the functions of
FXR in diverse biological pathways, including metabolism, liver
regeneration, anti-arthrosclerosis, tumor suppressor, and inhibition
of intestinal bacterial growth, have been recently published [2–6,10–
12]. Therefore, I will brieﬂy highlight functions of FXR in lipid and
glucose metabolism and also survey known FXR-related diseases and
human polymorphisms in the FXR gene.
3.1. FXR and bile acid metabolism
FXR plays a pivotal role in maintaining bile acid homeostasis by
regulating every aspect of bile acid metabolism including synthesis,
transport, and reﬁlling of the gall bladder [2–5,10,11,26]. FXR senses
elevated hepatic bile acid levels and inhibits hepatic bile acid
biosynthesis from cholesterol by induction of a metabolic repressor,
Small Heterodimer Partner (SHP) [2–5,10]. SHP is an unusual orphan
nuclear receptor that lacks a DBD [27] but acts as a bile acid-induced
transcriptional corepressor [28,29]. SHPhas features of anAF-2 cofactor,
i.e., that binds via LXXLLmotifs to the AF-2 domain of its target NRs [30].
SHP forms non-functional heterodimers with DNA binding activators,
including NRs, and inhibits their transcriptional activity [30,31]. SHP
inhibits expression of cholesterol 7α hydroxylase (CYP7A1), a rate-
limiting enzyme in the bile acid biosynthetic pathway, by blocking
transactivation of hepatic activators, LRH-1 andHNF-4, at the promoter.
In addition, FXR protects the liver from elevated bile acid levels by
regulating the expression of bile acid transporters [2,5,10,11]. FXR
inhibits the entry of intestinal bile acids into hepatocytes by repressing
the expression of Na+-taurocholate cotransporting polypeptide (ntcp),
a hepatic bile acid import transporter [32,33]. FXR also promotes the
efﬂux of bile acids from the liver by inducing expression of the bile salt
export pump (BSEP), the multidrug resistant-associated protein 2
(MRP2), and themultidrug resistance P-glycoprotein 3 (MDR3) [32,33].
These transporters, BSEP, MRP2, and MDR3, mediate the transport of
bile acids across the canalicular membrane into the bile duct. Bile acids,
togetherwith cholesterol and phospholipids, are themajor components
of bile which is stored in the gallbladder. Moschetta et al. [11,34]
demonstrated that FXR plays a critical role in preventing gallstone
formation by induction of bile acid transporters, BSEP andMDR2, which
results in increased bile acid levels in the gall bladder and prevents
cholesterol crystallization in the bile.
3.2. FXR and lipid metabolism
The function of hepatic FXR in regulating fatty acid, triglyceride,
and lipoprotein metabolism is complex. Previous clinical studies have
suggested an inverse relationship between the bile acid pool size and
triglyceride (TG) levels [3,5,6,10]. Treatment of dyslipidemic patients
with bile acid binding resin resulted in decreased cholesterol levels
but also in undesirable side effects of increased plasma TG levels and
VLDL levels [5]. Conversely, administration of bile acids to humans or
animals was shown to decrease plasma triglyceride levels and but
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clinical studies, activation of FXR by treatment with FXR agonists
resulted in decreased hepatic expression of SREBP-1c, a key lipogenic
activator, and increased expression of PPARα which promotes fatty
acid β-oxidation [2,5,10,11]. FXR activation also resulted in increased
expression of the VLDL receptor that promotes TG clearance. In
addition, FXR activation led to increased expression of apo CII that
coactivates lipoprotein lipase but decreased expression of apo CIII,
which functions as an inhibitor of lipoprotein lipase. Consistent with
these ﬁndings, activation of FXR transcriptional signaling by synthetic
or natural FXR ligands has been shown to have beneﬁcial metabolic
outcomes in some metabolic pathways but undesirable effects in
others, especially HDL biosynthesis [2–6,10,11]. In this regard,
understanding the precise molecular mechanisms by which FXR
activity is regulated in a gene-speciﬁc manner will be important in
order to identify molecular targets for such selective therapeutic
agents.
3.3. FXR and glucose metabolism
FXR plays an important role in controlling glucose levels
[2,5,6,10,11]. Normal glucose homeostasis was disrupted in FXR-null
mice with development of insulin resistance and hyperglycemia [35].
The insulin resistance and impaired insulin signaling in FXR-null mice
were likely due to elevated fatty acid levels [35]. Activation of FXR by
treatment with an agonist resulted in repression of the gluconeogenic
genes, PEPCK and glucose-6-phosphatase, and these effects were not
observed in FXR- or SHP-null mice, suggesting that the FXR/SHP
pathway plays a role in the regulation of hepatic glucose production
[35]. Consistent with these ﬁndings, activation of FXR resulted in
improved insulin sensitivity and glucose tolerance in diabetic obese
mice [36]. Treatment of diabetic mice with FXR agonists or hepatic
expression of constitutively active FXR-VP16 led to signiﬁcant
reduction of plasma glucose levels and improved insulin sensitivity
[36].
3.4. FXR-related human diseases and human polymorphisms
Consistent with the roles of FXR in regulating levels of metabolites,
FXR-null mice exhibited a cluster of metabolic abnormalities,
including dyslipidemia, cholesterol gall stone formation, hepatic
steatosis, cholestasis, hyperglycemia, insulin insensitivity, and arthro-
sclerosis [2–6,10,25]. Furthermore, new functions of FXR in liver
regeneration, defense mechanisms against intestinal bacteria, tumor
suppression, and diabetic kidney pathology have been discovered
[37–39]. Given that FXR is a critical metabolic regulator, genetic
variations in FXR could underlie FXR-related diseases. Several human
FXR polymorphisms have been reported [40,41]. Intrahepatic chole-
stasis of pregnancy (ICP) is characterized by liver impairment,
pruritus, and elevated maternal serum bile acids and can cause
premature delivery and intrauterine death. Williamson and collea-
gues have identiﬁed 4 novel heterozygous FXR variants in ICP, three
amino acid coding changes (M1V,W80R, andM173T) and one change
in the mRNA at the nucleotide before the ATG translation start codon
(G-1T) [41]. Using FXR expression plasmids encoding the variants,
they further showed functional defects in either translation efﬁciency
or activity for 3 of the 4 variants (G-1T, M1V, and M173T). Kim and
colleagues have analyzed FXR polymorphisms in European, African,
Chinese, and Hispanic–Americans populations [40]. Five polymor-
phisms in the coding region of FXR, including two rare single
nucleotide polymorphisms (SNPs) and a common SNP, were
identiﬁed in this study. The two rare SNPs within the hinge region
of FXR, C643T (H215Y), and G646T (A216S), and the SNP (G-1T) were
detected [40]. Expression of FXR target genes, SHP and OATP, but not
BSEP, was signiﬁcantly reduced in livers harboring the FXR (G-1T)
mutant, which suggests that the effects of the FXR polymorphism ontranscriptional responses may be gene-speciﬁc. Additional studies in
human populations with different susceptibilities to metabolic
disorders may provide valuable insights into FXR signaling that
could be exploited to treat diseases.
4. Transcriptional cofactors and post-translational
modiﬁcations (PTMs)
Despite recent advances in understanding of the biology of FXR,
the molecular basis of how FXR regulates expression of its target
genes and how the transcriptional activity of FXR is regulated are
relatively unexplored. In this section, I survey the transcriptional
cofactors (also called transcriptional coregulators) and PTMs that
potentially modulate FXR transcriptional signaling pathways. Unli-
ganded NRs have been shown to interact with SMRT/N-CoR
corepressor complexes and, thereby, repress their target genes
[9,42]. Likewise, unliganded or antagonist-bound FXR may be
associated with these transcriptional corepressors at its target genes
although this area is not well studied for FXR. In response to diverse
cellular signals including endocrine hormones and dietary lipids,
nuclear receptors such as FXR, recruit distinct combinations of
transcriptional cofactors to effectively regulate transcription of their
target genes [7,9,43]. These cofactors often profoundly modulate
nuclear receptor transcriptional signaling pathways by catalyzing
PTMs at two levels, ﬁrst, bymodifying histones at NR target genes, and
second, by modifying non-histone regulatory proteins including NRs
and the cofactors themselves [9,44]. Transcriptional cofactors,
therefore, not only catalyze PTMs but also serve as targets of PTMs
in response to cellular signals.
4.1. PTMs of histones
There are two classes of chromatin modifying cofactors that alter
chromatin structure and gene activity [44]. The ﬁrst class includes
histone modifying cofactors, which catalyze PTMs of histones [45].
PTMs of core histones serve as a code that increases or decreases
transcription by modulating transcriptional factor access to DNA via
altered local chromatin structure. Histone acetyltransferases (HATs)
or histone deacetylases (HDACs) covalently modify histones by
adding or removing, respectively, acetyl groups on lysine residues in
core histones [44,46]. Histone acetylation and deacetylation generally
correlate with gene activation and repression, respectively [44,46]. In
contrast to acetylation, histone methylation may result in either gene
activation or repression depending on the amino acid residues that
are methylated and type of methylation [44,47]. For instance,
methylation of histone H3 at Lys 4 (H3K4) is associated with gene
activation, whereas gene repression is associated with methylation of
H3K9 [48–51]. The functional importance of histone modifying
transcriptional cofactors in FXR/SHP-mediated feedback regulation
of hepatic bile acid synthesis was recently demonstrated [50,52,53]. In
response to bile acid signaling, SHP coordinately recruits chromatin
modifying cofactors, including HDACs and G9a lysine methyltransfer-
ase, to the promoter of the key bile acid biosynthetic CYP7A1 gene,
resulting in histone modiﬁcation and gene repression [50,52].
Importantly, blocking endogenous G9a methyltransferase activity in
liver by expression of a G9a dominant mutant reversed bile acid-
mediated CYP7A1 inhibition, which resulted in an enlarged gall
bladder and elevated bile acid pools [50].
The second type of transcriptional cofactors modulating chromatin
structure and gene activity is ATP-dependent chromatin remodeling
complexes such as Swi/Snf [54]. Using energy from ATP hydrolysis,
these chromatin remodeling complexes alter nucleosome structure by
disrupting DNA and histone interactions, resulting in either tran-
scriptionally activated accessible or transcriptionally repressive
closed chromatin conﬁgurations [55]. A Brg-1-containing Swi/Snf
complex was recently shown to interact with bile acid-activated FXR
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remodeling to an open chromatin conﬁguration and gene activation
[56]. These studies demonstrate that chromatin remodeling cofactors
as well as cofactors catalyzing PTMs have a role in regulation of bile
acid biosynthesis.
4.2. PTMs of non-histone regulatory proteins
In addition to PTM of histones, numerous studies have shown that
transcriptional cofactors, such as HATs and HDACs, also modulate
activity of non-histone proteins by post-translational acetylation and
deacetylation, respectively [8,9,57]. Transactivation by important
metabolic regulators including FXR, LXR, SREBP-1, Foxo-1, HNF-4,
p53, and PGC-1α was substantially modulated by their acetylation
status [58–64]. Acetylation and deacetylation of these proteins can
increase or decrease their transcriptional activity by altering DNA
binding, interaction with other cofactors, cellular localization, or
protein stability [58–64]. For instance, acetylation of p53, SREBP-1c,
and HNF-4 increased their ability to bind to the DNA [59,62,64],
whereas acetylation of Foxo-1 and FXR decreased their DNA binding
and transactivation ability [58,63]. Interestingly, acetylation of p53 at
different sites selectively affected biological pathways by targeting
different subsets of p53 target genes [65]. Since FXR also activates or
inhibits subsets of target genes, it will be interesting to test whether
PTMs of FXR also contribute to such different gene-speciﬁc functional
outcomes.
5. FXR and transcriptional cofactors
5.1. Bile acids as signaling molecules
It is now clear that bile acid signaling pathways in hepatocytes are
complex (Fig. 1). Bile acids facilitate digestion of lipid-soluble
nutrients but also function as signaling molecules that mediate
integrative metabolic regulation by activating both cellular signaling
kinases and nuclear receptors, primarily FXR [2,6,17,66]. In addition,
recent studies have identiﬁed a GPCR, TGR5, as a membrane bile acid
receptor [6,16]. An intriguing role of FXR as an integrator of a gut/liver
endocrine regulatory axis was also demonstrated [67]. FXR activation
induces expression of FGF-15 in the small intestine. The secreted FGF-
15 binds to a liver transmembrane receptor tyrosine kinase, FGF-15
receptor 4 (FGFR4), and triggers cellular signaling kinase cascades in
hepatocytes. Activation of bile acid receptors and cell signalingA
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Fig. 1. FXR transcriptional responses by PTMs and cofactor interaction in response to bile ac
primarily FXR, and a membrane GPCR TGR5. Intestinal FGF-15 (FGF-15 is the mouse hom
membrane receptor tyrosine kinase, FGFR4, and triggers cellular kinase signaling cascade
pathways, interaction of FXR with transcriptional cofactors is changed, which results in altepathways, such as ERK, JNK, PKB (Akt), and PKC, results in altered
expression of hepatic genes involved in the regulation of lipid and
glucose metabolism [2,17,66]. In response to these multiple genomic
and non-genomic bile acid-activated signaling pathways, FXR differ-
entially interacts with its transcriptional cofactors, resulting in the
recruitment of distinct combinations of transcriptional cofactor
complexes to its target genes. FXR cofactors catalyze PTMs of histones
and FXR itself, to effectively modulate transcription of target genes
(Fig. 1).
5.2. Potential FXR cofactors
About a dozen transcriptional cofactors that can potentially
modulate FXR transactivation ability have been reported (Table 1).
In general, interactions of FXR with coactivators, including Brg-1,
p300, CARM1, PRMT1, and ASCOM, are increased after treatment with
FXR agonists, and the coactivators are recruited to FXR target genes,
which results in histone modiﬁcation or chromatin remodeling and
increased gene transcription. Interestingly, some of these cofactors,
including p300 and SIRT1, acetylate and deacetylate not only histones
at FXR target genes but also FXR itself [58,69]. Although not much
studies on corepressors for FXRwere done, based on other NRs such as
PPAR, LXR, and TR [42], this is a likely possibility.
5.2.1. PGC-1α coactivator
Edwards and colleagues reported that PGC-1α, a critical metabolic
regulator in mitochondrial biogenesis and function, increases both
FXR levels and its transactivation activity [68]. PGC-1α functions as a
transcriptional coactivator of FXR that directly interacts with FXR and
enhances its transactivation activity. PGC-1α also increases transcrip-
tion of the FXR gene by coactivation of PPARγ and HNF-4 resulting in
increased FXR mRNA levels. Hepatic expression of PGC-1α and FXR
was increased during fasting, which results in decreased plasma TG
levels and increased fatty acid β-oxidation needed to supply energy
demands during fasting [68].
5.2.2. P300 acetylase and SIRT1 deacetylase
P300 catalyzes covalent modiﬁcation of acetylation at lysine
residues in histones and transcriptional factors/cofactors. Recently,
Fang et al. showed that p300 acts as a coactivator for FXR in SHP gene
induction by catalyzing acetylation of K9/K14 of histone H3, which are
activating histone modiﬁcations [69]. P300 was also shown to
acetylate FXR. However, unexpectedly, acetylation of FXR by p300ction
FXR Transcriptional Responses
RXR FXR
FXR targets
histone PTMs
P Ac
P Ac
FXR PTMs
Nucleus
Cytoplasm
FXR/cofactor
id signaling. Bile acids activate cellular kinases (JNK, ERK, PKB, PKC), nuclear receptors,
ologue of human FGF-19), upon induction by bile acid-activated FXR, binds to a liver
s in hepatocytes. In response to these multiple bile acid-activated cellular signaling
red PTMs of FXR as well as histones to effectively modulate expression at target genes.
Table 1
Reported Transcriptional cofactors of FXR.
Cofactors Cellular function Regulation of FXR signaling References
PGC-1α A key metabolic regulator mitochondria
function oxidative phosphorylation
A coactivator of FXR during fasting increases FXR transactivation
increases expression of the FXR gene
Zhang et al. [68]
p300 Transcriptional integrator
Lys acetylase
Acetylates H3K9/14 at the FXR targets acetylates FXR at K217 dynamic
transcription of FXR targets
Kemper et al. and Fang et al. [58,69]
SRC-1 General NR AF2 coactivator
Lys acetylase
FXR agonists increases SRC-1 interaction with FXR LBD, increases
FXR transactivation
Lew et al. and Wang et al. [70,71]
SIRT1 NAD+-dependent deacetylase A
life-longevity protein
Deacetylates H3K9/14 at the FXR targets deacetylates FXR dynamic
transcription of FXR targets
Kemper et al. and Fang et al. [58,69]
Brg-1 An ATPase of Swi/Snf complexes FXR agonist increases interaction with FXR increases FXR transactivation
mediates chromatin remodeling at FXR targets
Miao et al. [72]
CARM1 Arg methyltransferase FXR agonist increases interaction with FXR increases FXR transactivation
methylates H3R17 at the BSEP promoter
Ananthanarayanan et al. [48]
PRMT1 Arg methyltransferase FXR agonist increases interaction with FXR increases FXR transactivation
methylates H4R3 the BSEP and SHP promoters
Rizzo et al. [49]
ASCOM a coactivator complex containing
ASC-2 and H3K4 Lys
methyltransferases (MLL3/4)
FXR agonist increases ASCOM recruitment to targets tri-methylates H3K4
and gene activation impaired FXR signaling and disrupted BA levels by
mice expressing inactive MLL3 mutant
Kim et al. [51]
GPS2 A subunit of the N-coR corepressor
complex
Interacts with FXR increases the CYP8B1 expression by activated FXR by
promoting the enhancer and promoter interaction
Sanyal et al. [73]
Ku proteins DNA-dependent kinase
catalytic subunits
FXR corepressor interacts with the hinge region of FXR decreases FXR
activity of the BSEP gene
Ohno et al. [74]
DRIP205 Transcription mediator FXR agonist increases interaction with FXR increases FXR transactivation
binding with RXR is important for DRP205 action
Pineda Torra et al. [75]
TRRAP Transcription mediator FXR agonist increases interaction with FXR increases FXR transactivation Unno et al. [76]
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binding of the FXR/RXRα heterodimer [58] (see next section).
Interestingly, down-regulation of p300 altered expression of SHP
and other metabolic FXR target genes involved in lipoprotein and
glucose metabolism, such that beneﬁcial lipid and glucose proﬁles
would be expected [69].
SIRT1 is a NAD+-dependent deacetylase that removes acetyl
groups from modiﬁed lysines in both histones and non-histone
regulatory proteins [77,78]. SIRT1 senses cellular nutrient levels and
functions as a key metabolic regulator by modulating activity of
metabolic regulators via protein deacetylation. Our group recently
reported SIRT1 profoundlymodulates FXR transcriptional signaling by
deacetylation of both histones and FXR [58]. On one hand, SIRT1
increases the transactivation potential of FXR by deacetylating FXR
because heterodimerization of FXR with RXRα and binding to the
DNA is impaired by acetylation of FXR. On the other hand, SIRT1
deacetylates histones at the SHP promoter, which is expected to
maintain transcriptional silencing. These paradoxical effects of SIRT1
and p300 on dynamic FXR transcriptional signaling will be discussed
in detail in following sections.
5.2.3. Brg-1, an ATPase of Swi/Snf complexes
A recent study using in vivo chromatin remodeling assays and
functional studies along with siRNA approaches has identiﬁed Brg-1,
an ATPase in Swi/Snf complexes, as a FXR coactivator [72].
Interestingly, Miao et al. [72] recently showed that Brm and Brg-1,
two ATPases of Swi/Snf complexes, have distinct roles in FXR/SHP-
mediated feedback regulation of hepatic bile acid biosynthesis. While
Brg-1 is a FXR coactivator for SHP gene induction, Brm is a critical
component of the SHP complexes, which inhibit expression of both
the CYP7A1 gene and the SHP gene. Activation of FXR by agonists in
HepG2 cells or mice in vivo increased the interaction of FXR with Brg-
1 and increased occupancy of FXR and Brg-1 at the SHP promoter.
5.2.4. Histone methyltransferases, CARM1, PRMT1, and ASCOM
Ananthanarayanan and colleagues originally reported that CARM1
interacts with FXR and enhances the transactivation ability of FXR
[48]. In response to treatment with a FXR agonist, occupancy of
CARM1 and FXR was increased at the promoter of BSEP, a known FXR
target gene that functions as an ATP-dependent canalicular bile acid
transporter. Increased occupancy of CARM1 at the BSEP promoterresulted in increased methylation at Arg-17 of histone H3 and gene
activation. Fiorucci and colleagues have also identiﬁed PRMT1 as a
FXR coactivator [49]. Treatment with a semi-synthetic FXR agonist,
6E-CDCA, resulted in increased interaction of FXR with PRMT1 and
increased mRNA levels of the FXR target genes, BSEP and SHP. After
treatment with 6E-CDCA, both the occupancy of PRMT1 and histone
H4 methylation at the promoters of the BSEP and SHP genes were
increased. Lee and colleagues recently demonstrated that a coacti-
vator complex ASCOM that contains activating signal cointegrator-2
(ASC-2), the histone H3 K4 methyltransferases, MLL3 and MLL4, is a
coactivator of FXR [51]. ASC-2, MLL3, and MLL4 were recruited to FXR
target genes in a ligand-dependent manner, resulting in H3K4
trimethylation and gene activation. Importantly, expression of FXR
target genes was partially impaired in mice expressing a catalytically
inactive MLL3 mutant, and these mice exhibited disrupted bile acid
homeostasis.
5.2.5. GPS2, DRIP205, TRRAP, and Ku proteins
Treuter and colleagues recently identiﬁed GPS2, a stoichiometric
subunit of the N-CoR corepressor complex, as a novel FXR-interacting
protein in the regulation of a major bile acid biosynthetic gene,
CYP8B1 [73]. From chromatin immunoprecipitation and functional
studies using siRNA, they found that the CYP8B1 genewas a direct FXR
target gene and that GPS2 augments expression of the CYP8B1 gene
by the activated FXR via facilitating physical interaction between the
CYP8B1 enhancer and promoter regions [73]. DRIP205 and TRRAP
were also identiﬁed as transcriptional coactivators of FXR from in
vitro interaction studies and cell-based functional reporter studies
[75,76]. Treatment with a FXR agonist including bile acids increased
the interaction of FXR with these cofactors. Gain or loss of function
studies showed that these cofactors augment the transactivation
ability of FXR. Cell-based reporter assays using a RXRα heterodimer-
ization-deﬁcient FXR mutant (L433R) revealed that FXR heterodi-
merization with RXRα is important for coactivation of FXR activity by
DRIP205 [75]. DNA-dependent protein kinase catalytic subunits,
Ku80, and Ku70, were also identiﬁed as FXR-interacting proteins
that function as corepressors [74]. The Ku proteins interacted with the
hinge region of FXR, and expression of these proteins decreased the
promoter activity of the BSEP gene. These interactions suggest that
phosphorylation of FXR may also be an important regulatory PTM. In
this regard, it will be interesting to determine if kinase signaling
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have been analyzed in vitro or in cultured cells, so it will be important
to examine whether they modulate FXR transcriptional activity
in vivo.
6. Acetylation of FXR in health and disease
Recent studies have shown that PTMs of FXR profoundly modulate
its transactivation ability in response to cellular signals (Fig. 2). Fang
et al. recently reported that p300 acetylates FXR in vitro and in cells
[69]. By examination of the acetylation of FXR in vivo in normal and
disease model mice, our group further obtained evidence for
biological functions of acetylation of FXR in normal and disease
conditions [58]. FXR acetylation was normally dynamically regulated
by p300 acetylase and SIRT1 deacetylase in response to bile acid
signaling or fasting/feeding cycles in normal mice [58]. In contrast,
FXR acetylation was constitutively highly elevated in livers of diet-
induced obese mice and ob/ob mice, two mouse models of the
metabolic syndrome [58]. Most previous gene regulation studies have
been focused on either PTMs of histones or PTMs of non-histone
regulatory proteins, but these studies showed that FXR transcriptional
signaling was modulated both by acetylation of FXR and acetylation of
histones at the target gene.
6.1. Dynamic FXR acetylation in normal animals
Lys-217 in the hinge region of FXR was identiﬁed by tandem mass
spectrometry analysis as a major acetylation target site for p300.
Acetylation at Lys-157 in the DNA binding domain was also detected.
Consistent with roles of the NR hinge region in protein ﬂexibility to
allow for simultaneous receptor dimerization and DNA binding [7,43],
acetylation of FXR at Lys-217 inhibited heterodimerization with RXRα
and binding of FXR/RXRα heterodimers to DNA/chromatin [58].
Consistent with these observations, functional studies showed that
FXR acetylation, especially at Lys-217, leads to decreased FXR
transactivation ability. As summarized in Fig. 3, in response to FXR
activating signals, including bile acids, feeding, or synthetic agonists,
interaction of FXR with p300 is increased, whereas that of SIRT1 is
decreased. Subsequently, occupancy of FXR and p300 is increased at
the SHP promoter, whereas that of SIRT1 is decreased, resulting in
acetylation of histones. Acetylation of histones H3 at K9/K14 by p300
is associated with gene activation and is probably the major factor in
the transcriptional activation of the SHP gene. However, p300 also
catalyzes acetylation of FXR and inhibits heterodimerization with
RXRα and DNA binding. The fate of FXR, presumably dissociation from
the promoter by this mechanism, is not clear. This apparently
paradoxical effect may be an important mechanism to terminate
transcriptional responses of FXR to a stimulus, such as feeding or bilePTMs of
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Fig. 2. Reported PTMs of FXR. FXR is a target of PTMs, including acetylation (Ac), phosphoryla
was also shown to be ubiquitinated but target sites are not known. Amino acid targets of PTM
shown below. The indicated sequence motifs are conserved in mouse FXR sequences.acid signaling, which is essential in a dynamically regulated system to
maintain homeostasis.
During the fasting state, which results in increased SIRT1 levels
and activity, FXR may be deacetylated by SIRT1 and undergo
ubiquitination–proteasomal degradation or rebind to the SHP pro-
moter (Fig. 3). In the fasting state, expression of FXRmay be increased
by PGC-1α [68] but occupancy of SIRT1 at the SHP promoter is
increased and histones are deacetylated, so that gene expression
remains at a low basal level. Therefore, acetylation and deacetylation
of FXR appear to be a dynamic process in response to ﬂuctuating bile
acid levels during fasting and feeding cycles and are tightly balanced
by the opposing actions of p300 and SIRT1. This scenario is analogous
to the modulation of PGC-1α activity by opposing actions of GCN5
acetylase and SIRT1 deacetylase [60,61]. Although GCN5 potentially
increases transcription of PGC-1α target genes by acetylating histone
H3, GCN5 also directly acetylates PGC-1α at multiple lysine residues
and negatively regulates its coactivator potential. Conversely, SIRT1
deacetylates and increases the coactivator potential of PGC-1α.
6.2. Elevated FXR acetylation in disease
In high-fat diet-induced obese mice, ob/ob mice, or mice depleted
of hepatic SIRT1 by adenoviral expressed siRNA, FXR acetylation levels
were constitutively and highly elevated with deleterious gene
expression patterns and metabolic outcomes [58]. Interaction of FXR
with p300 was constitutively highly elevated, whereas FXR interac-
tion with SIRT1 and its heterodimer partner, RXRα, was dramatically
decreased [58]. Heterodimerization with RXRα and subsequently
binding of the heterodimer to the DNA were impaired, which may
result in aberrant FXR transcriptional pathways in these metabolic
disease conditions (Fig. 4). Whether elevated FXR acetylation is a
cause or consequence of deleterious metabolic effects remains
unclear. Low activity and/or levels of SIRT1 in these metabolic disease
model mice may contribute to elevated FXR acetylation so that FXR
acetylation is a consequence of the metabolic abnormalities. Alterna-
tively, aberrant expression of metabolic target genes due to
dysregulated FXR transcriptional pathways may underlie metabolic
abnormalities, which is consistent with elevated FXR acetylation
levels in both diet-induced obese and ob/obmice. However, a primary
role for highly elevated FXR acetylation does not rule out a vicious
positive feedback loop in which detrimental metabolic outcomes
result in enhancement of the elevated FXR acetylation. These ﬁndings
provide an intriguing correlation between elevated FXR acetylation,
decreased FXR transactivation ability, and deleterious effects in
metabolic disease states. Dynamic acetylation and deacetylation of
FXR in normalmicemay be required for activation of FXR target genes,
while continuously elevated FXR acetylation in the diseased states
blocks activation. An interesting question is whether acetylation FXR
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Fig. 3. Dynamic acetylation/deacetylation of FXR in normal physiology. In response to low bile acid levels during fasting, occupancy of SIRT1 at the SHP promoter is increased and
histones are deacetylated, so that gene expression remains at a low basal level. In response to FXR activation signals such as bile acids after feeding, interaction of FXR with p300 and
SIRT1 is altered and, subsequently, occupancy of FXR and p300 is increased at the SHP promoter, resulting in acetylation of histones H3 at K9/K14 and gene activation. P300 also
catalyzes acetylation of FXR and inhibits heterodimerization with RXRα, which then results in dissociation from the promoter and transcriptional termination. The fate of the
dissociated FXR has not been clearly determined. FXR may be deacetylated by SIRT1 and undergo ubiquitination–proteasomal degradation or rebind to the SHP promoter.
Acetylation and deacetylation of FXR, therefore, appear to be a dynamic process in response to ﬂuctuating bile acid levels during fasting and feeding cycles.
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target genes or whether acetylation has gene-speciﬁc effects.
6.3. Remaining questions
There are important remaining questions about the molecular
regulation of FXR activity by PTMs. Does FXR acetylation at Lys-157 or
Lys-217 lead to gene-speciﬁc changes in FXR transcriptional
responses by forming complexes with different combinations of
transcriptional cofactors, resulting in different functional conse-
quences? Also, an interesting still unresolved question is whether
elevated FXR acetylation at K217 is a cause or consequence of
metabolic diseases. Transgenic knock-in mice expressing acetylation
mimic or defective mutants of Lys-217 or transient expression of
these mutants using adenoviral delivery would help address these
questions. It will be important to determine whether kinases
downstream of the bile acid signaling pathways inﬂuence FXR
acetylation and identify which abnormal cellular kinase signalingPathophysiology 
FXR
p300Ac
Impaired DNA binding as a heterodimer w/ RXRα
Dysregulated FXR transcriptional activity and pathways 
due to aberrant PTMs (Ac) of FXR and cofactor interaction
FXR targets
FXR RXRα
Fig. 4. Constitutively highly elevated FXR acetylation in pathophysiology. In diet-
induced obese (DIO) mice and leptin-deﬁcient ob/ob mice, FXR acetylation levels are
constitutively and highly elevated with deleterious gene expression patterns and
metabolic outcomes. Interaction of FXR with p300 is highly elevated, whereas FXR
interaction with SIRT1 and its heterodimer partner, RXRα, is dramatically decreased.
Aberrant PTMs and inappropriate FXR/cofactor complexes contribute to dysregulation
of FXR transcriptional activity and pathways in metabolic disease states.pathways underlie the elevated acetylation of FXR in disease
conditions. While most studies of FXR have focused on the liver, it
will be also interesting to examine whether elevated FXR acetylation
is detected in other FXR-related diseases such as cancer and aging, and
in other tissues.7. FXR and other post-translational modiﬁcations
7.1. FXR phosphorylation
Staels and colleagues recently reported that calcium-dependent
PKC kinase phosphorylates FXR at Ser-135 and Ser-154, in the DBD
(Fig. 2) [79]. Using pharmacological activators or inhibitors of PKC,
they showed that phosphorylation of FXR by PKC promoted FXR
interaction with PGC-1α and increased its transactivation activity.
Consistent with these results, a PKC phosphorylation-defective FXR
mutant exhibited decreased ligand-dependent FXR transactivation
[79]. Since bile acids activate PKC, it will be interesting to examine
whether bile acids increase PKC-mediated phosphorylation of FXR.
Enhanced activity of FXR as a result of post-translational phosphor-
ylation was also demonstrated by Schneider and colleagues, who
showed that the membrane protein ATPase class 1 type 8B member
(called familial intrahepatic cholestasis 1 (FIC1) protein) activates
FXR via protein phosphorylation [80]. FIC1 is critical for normal bile
acid transport, and mutation of this gene leads to a spectrum of liver
diseases including intrahepatic cholestasis [33]. Using phosphoryla-
tion-defective or mimic FXR mutants, along with pharmacological
inhibitors and siRNA approaches, they showed that PKC zeta
phosphorylates FXR at Thr-442, which is important for the FIC1 effect
(Fig. 2) and that phosphorylation of FXR at Thr-442 augments
transactivation ability of FXR and increases its nuclear localization.
These ﬁndings show that the membrane bound FIC1 signals to FXR via
PKC zeta and that FIC1-related liver disease is likely associated with
downstream effects of decreased FXR activity in the regulation of bile
acid homeostasis.
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Compared to FXR acetylation and phosphorylation studies, post-
translational ubiquitination and sumoylation of FXR have not been
thoroughly examined. Our group recently showed that treatment
with MG132, a proteasome inhibitor, markedly increased FXR levels,
suggesting that FXR may undergo proteosomal degradation [58].
Furthermore, FXR was robustly ubiquitinated in vitro and in cells.
However, the residues in FXR that are ubiquitinated are not known.
The half-lives of FXRwere determined to be 5–6 h for ligand-activated
FXR wild type and about 2 h for acetylation defective mutants [58],
indicating that FXR acetylation increases its stability. Phosphorylation
of FXR in response to bile acid signaling may modulate ubiquitination
and proteasomal degradation of FXR. Supporting such a possibility, we
recently reported that in response to treatment with bile acid or FGF-
19, activated ERK kinase phosphorylates SHP at Ser-26, which
increases stability of SHP by inhibiting ubiquitination at Lys-122 and
Lys-123 and proteasomal degradation [56].
A recent study reported that Lys-279 in the LBD of FXR is a
potential sumoylation site in the regulation of intestinal innate
immunity (Fig. 2) [81]. FXR contains at least two potential sumoyla-
tion consensus sites (WKXE/D), Lys-122 or Lys-277, where W
indicates any hydrophobic amino acid and X indicates any amino
acid. Overexpression of the K277R mutant impaired inhibition of the
expression of the TNFα gene caused by synthetic FXR agonist 6E-
CDCA (also called INT-747), whereas FXR wild type showed full trans-
repression activity [81]. Additional studies will be required to
unequivocally demonstrate that Lys-277 is the major sumoylation
site in FXR and to directly demonstrate the functional roles of
sumoylation in FXR transcriptional signaling pathways.
8. Concluding remarks
In response to constant nutrient and hormonal ﬂuctuations, the
body must maintain metabolic homeostasis by altering expression of
genes in metabolic tissues. The inability to sense and adapt to these
ﬂuctuations, which leads to over accumulation of metabolites, plays a
crucial causative role in the development of metabolic disorders. The
nuclear bile acid receptor FXR senses elevated bile acid levels and
connects bile acid signaling with altered gene activity to maintain
lipid and glucose homeostasis. Dysregulation of FXR activity and
transcriptional pathways due to aberrant PTMs and inappropriate
FXR/cofactor complexes could be a key determinant in the develop-
ment of metabolic disease. Therefore, targeting these abnormal PTMs
and transcriptional cofactors of FXR in disease states to correct altered
transcriptional signaling may represent new molecular strategies for
development of pharmacological agents to treat the metabolic
syndrome. For example, FXR synthetic ligands that cause differential
interaction with speciﬁc groups of transcriptional cofactors and alter
FXR PTMs might be developed into therapeutic agents. Furthermore,
inhibitors of histone modifying enzymes such as histone deacetylases
and methylases have emerged as effective therapeutic options [82–
84]. Therefore, combinatorial use of FXR ligands together with these
epigenomic drugs that speciﬁcally target histone modifying enzymes
may provide new strategies for developing next generation drugs for
the treatment of FXR-related diseases such as metabolic syndrome
and cancer.
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